



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 401/04, A61K 31/506	A1	(11) International Publication Number: WO 00/29403 (43) International Publication Date: 25 May 2000 (25.05.00)
<p>(21) International Application Number: PCT/KR99/00669</p> <p>(22) International Filing Date: 9 November 1999 (09.11.99)</p> <p>(30) Priority Data: 1998/49164 17 November 1998 (17.11.98) · KR</p> <p>(71) Applicant (for all designated States except US): YUHAN CORPORATION [KR/KR]; 49-6, Taebang-dong, Tongjak-ku, Seoul 156-020 (KR).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): LEE, Jong, Wook [KR/KR]; 50-5, Byulyang-dong Kwachon-shi, Kyonggi-do 427-040 (KR). LEE, Bong, Yong [KR/KR]; Dongshin Apt. #109-1406, Jungja-dong, Jangan-ku, Suwon-shi, Kyonggi-do 440-300 (KR). KIM, Chang, Seop [KR/KR]; Hyundai 2nd Apt. #410-203, 1343 Sa-dong, Ansan-shi, Kyonggi-do 425-172 (KR). LEE, Seung, Kyu [KR/KR]; Mokryun Woosung Apt. #305-1007, Hogae-dong, Dongan-ku, Anyang-shi, Kyonggi-do 431-080 (KR). LEE, Song, Jin [KR/KR]; Poongrim Apt. #102-1202, Ojeon-dong, Euiwang-shi, Kyonggi-do 437-070 (KR).</p>	<p>(74) Agent: OH, Kook, Jin; Yuhan Research Center, 27-3, Tangjeong-dong, Kunpo-shi, Kyonggi-do 435-715 (KR).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	

(54) Title: **NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF**

(57) Abstract

The present invention relates to novel pyrimidine derivatives and pharmaceutically acceptable non-toxic salts thereof which possess an excellent inhibitory activity against gastric acid secretion, a pharmaceutical composition containing the same as an active ingredient, and a process for the preparation thereof.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF

Field of the Invention

5

The present invention relates to novel pyrimidine derivatives and pharmaceutically acceptable non-toxic salts thereof which possess an excellent inhibitory activity against gastric acid secretion, a pharmaceutical composition containing the same as an active ingredient,
10 and a process for the preparation thereof.

Background of the Invention

For the treatment of peptic ulcer disease, various drugs such as
15 antacid, anticholinergic agents, H₂-receptor antagonist and proton pump inhibitor have been used. The advent of proton pump inhibitors has rekindled research activities in this field.

However, it has been pointed out that the irreversible mode of
20 action by proton pump inhibitors may induce undesirable effects. Accordingly, various attempts to develop a reversible proton pump inhibitor (i.e., reversible acid pump antagonist) are being actively made. For example, European Patent Nos. 322,133 and 404,322 disclose quinazoline derivatives, European Patent No. 259,174 describes quinoline
25 derivatives, and WO 91/18887 offers pyrimidine derivatives, as reversible proton pump inhibitors.

Further, the present inventors have also reported quinazoline derivatives in WO 94/14795 and pyrimidine derivatives in WO 96/05177
30 and WO 98/43968.

Summary of the Invention

The present inventors have carried out further research to develop reversible acid pump antagonists with improved efficacy; and, as a result, have discovered that pyrimidine derivatives having one or more halogen groups at the 5- or 6-position of a pyrimidine nucleus or at the
5 tetrahydroisoquinoline group of the 4-position of the pyrimidine nucleus exhibit excellent acid pump inhibition effects and inhibitory activity against gastric acid secretion.


Accordingly, it is a primary object of the present invention to
10 provide novel pyrimidine derivatives having one or more halogen groups at the 5- or 6-position of a pyrimidine nucleus or at the tetrahydroisoquinoline group of the 4-position of the pyrimidine nucleus, and pharmaceutically acceptable non-toxic salts thereof.

15 It is another object of the present invention to provide processes for preparing said compounds.

It is a further object of the present invention to provide pharmaceutical compositions for treating gastrointestinal diseases
20 containing the same as an active ingredient.

Detailed Description of the Invention

In accordance with one aspect of the present invention, there are
25 provided novel pyrimidine derivatives of formula (I) or pharmaceutically acceptable non-toxic salts thereof:



(I)

wherein R_1 is hydrogen, methyl, or halogen and R_2 , R_3 , R_4 , R_5 and R_6 are, independently each other, hydrogen or halogen, provided that when all of R_3 , R_4 , R_5 and R_6 are hydrogen, R^1 and R^2 are, independently
5 each other, halogen.

Among the pyrimidine derivatives of the present invention, preferred are those wherein R_1 , R_2 , R_3 , R_4 , R_5 and R_6 are independently fluoro or chloro.

10

The present invention also includes, within its scope, pharmaceutically acceptable non-toxic salts of the compounds of formula (I). The non-toxic salts, within the scope of the present invention, may include inorganic or organic salts, such as hydrochloride, maleate, sulfate,
15 phosphate, mesylate, nitrate, tartrate, fumarate, citrate, acetate. In addition, conventional acidic salt forms used in the field of anti-ulcer agents may be included. Such salts may be prepared in accordance with any of the conventional methods.

20


The present invention further includes, within its scope, processes for the preparation of the compounds of formula (I-1) and (I-2). The compounds of the formula (I-1) and (I-2) may be prepared in accordance with the following methods.

25 Method for preparation of formula (I-1)

The compound of formula (I-1) may be prepared by halogenating the corresponding hydroxy group of a compound of formula (II) in accordance with Scheme 1 described below.

30

Scheme 1.



wherein R_1 is hydrogen, methyl, or halogen and R_2 , R_3 , R_5 and R_6 are,
 5 independently each other, hydrogen or halogen, provided that one or more
 of R_3 , R_5 and R_6 is/are halogen; and R_3' , R_5' and R_6' is independently
 hydrogen or hydroxy, provided that one or more of R_3' , R_5' and R_6' are
 hydroxy.

10 In the process of Scheme 1, when halogen is fluoro, the compound
 of formula (I-1) may be prepared by adding (diethylamino)sulfur
 trifluoride to the solution of the compound of formula (II) in an
 appropriate solvent. Suitable solvents for this reaction may include
 chloroform and dichloromethane. The reaction temperature preferably
 15 ranges from -78°C to 25°C and the reaction time preferably ranges from
 4 to 18 hours.

In the process of Scheme 1, when halogen is chloro, the compound
 of formula (I-1) may be prepared by adding thionyl chloride to the
 20 solution of the compound of formula (II) in an appropriate solvent.


The compound of formula (II) may be prepared in accordance with
 conventional methods (e.g., WO 98/43968).

25 Method for preparation of formula (I-2)

The compound of formula (I-2) which R_3 , R_5 and R_6 are hydrogen may be prepared by reacting a compound of formula (III) with a compound of formula (IV) in accordance with Scheme 2 described below.

5

Scheme 2



10

wherein R_1 is hydrogen, methyl, or halogen and R_2 and R_4 are, independently each other, hydrogen or halogen, provided that when R_4 is hydrogen, R_1 and R_2 are, independently each other, halogen.

15

Suitable solvents for this reaction include dimethylformamide, 1,4-dioxane, dimethyl sulfoxide, and propylene glycol. The reaction temperature preferably ranges from 80°C to 140°C and the reaction time preferably ranges from 2 to 5 hours.

20

The compounds of formula (III) may be prepared in accordance with the same method as described in WO 96/05177. And also, tetrahydroisoquinolines substituted with fluoro or chloro group at 5-, 6-, or 7-position of tetrahydroisoquinoline, which are useful as an intermediate for preparing the compound of formula (III), may be prepared in accordance with a known method (e.g., J. Org. Chem., 1991,

25

56, 6034).

The present invention further includes, within its scope, pharmaceutical compositions for treating gastrointestinal diseases, which
5 comprise a therapeutically effective amount of the pyrimidine derivative of formula (I) or a pharmaceutically acceptable non-toxic salt thereof as an active ingredient, and a pharmaceutically acceptable carrier, excipient and/or other additives, if necessary. The active ingredient present in the composition may range from 0.1% to 99.9% by weight thereof.

10 The pharmaceutical composition of the present invention may be formulated in accordance with conventional methods. For example, the pharmaceutical composition may be formulated into various forms such as solution, suspension or emulsion in an oily or aqueous vehicle, which may
15 contain conventional additives such as a dispersant, suspending agent, or emulsifiers, stabilizer and the like. Alternatively, the active ingredient may be formed into a dried powder that may be dissolved in sterile pyrogen-free water before use.

20 The compounds of the present invention may be administered, either orally or intraperitoneally, in an amount ranging from 0.1 to 500 mg/kg per day, preferably from 1.0 to 100 mg/kg per day, to human beings or animals suffering from gastrointestinal diseases, depending on the age and body weight of the patient, the nature and severity of the illness and
25 so on. The compounds of the present invention may be formulated for administration in unit dose or multi-dose containers.

The following Examples and Test Examples are given for the purpose of illustration only, and are not intended to limit the scope of the
30 invention.

Preparation 1: Preparation of 1-methyl-1,2,3,4-tetrahydroisoquinoline

Step 1 : N-(2-phenylethyl)acetamide

After phenethylamine (37.8ml, 0.3mol) and triethylamine (42ml, 0.3mol) were dissolved in dichloromethane (200ml), acetyl chloride
5 (20.7ml, 0.3mol) was dropwise added thereto, while maintaining the reaction temperature below 0°C. The resulting solution was stirred for 10 minutes at room temperature, washed with water, dried over anhydrous magnesium sulfate, and concentrated in vacuo to give 45.8g of the titled compound as a white solid.

10

Step 2 : 1-methyl-3,4-dihydroisoquinoline

The compound (25.3g, 154.8mmol) prepared in Step 1 above was added to polyphosphoric acid (250g) and then stirred for 1.5 hours at
15 160°C. The reaction mixture was poured into ice water, neutralized with ammonia solution, and extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated in vacuo. The resulting residue was subjected to silica gel column chromatography (eluent : methanol/dichloromethane = 1/20) to give 21.8g of the titled
20 compound as an oily substance.

Step 3 : 1-methyl-1,2,3,4-tetrahydroisoquinoline

To the suspension of sodium borohydride (5.28 g, 138mmol) in
25 ethanol, was added the compound (19.8 g, 133.8mmol) prepared in Step 2 above. The reaction mixture was stirred for 1 hour at room temperature, cooled to below 5°C, acidified with diluted hydrochloric acid, neutralized with sodium hydroxide solution, and extracted with ethyl acetate. The ethyl acetate layer was dried over anhydrous sodium sulfate and
30 concentrated in vacuo to give 18.5g of the titled compound.

Preparation 2: Preparation of 1-methyl-7-fluoro-1,2,3,4-tetrahydroisoquinoline

Step 1 : 6,10b-dihydro-10b-methyl-5H-oxazolo[2,3-a]isoquinolin-2,3-dione

5 To the solution of N-[2-(4-fluorophenylethyl)acetamide (5.8g, 32mmol) prepared in accordance with the same procedure as in Step 1 of Preparation 1 in dichloromethane (15ml), oxalyl chloride (3.07ml, 1.1eq.) was dropwise added. The reaction mixture was stirred for 30 minutes at room temperature and cooled to below -10°C. Aluminum chloride (5.1g,
10 1.2eq.) was added to the reaction mixture and then it was stirred for 18 hours at room temperature. 1N hydrochloric acid solution was added to the reaction mixture, which was then stirred for 1 hour at room temperature. The organic layer was washed with brine and concentrated in vacuo to give 5.2g of the titled compound.

15

Step 2 : 1-methyl-7-fluoro-3,4-dihydroisoquinoline

To 6,10b-dihydro-10b-methyl-5H-oxazolo[2,3-a]isoquinolin-2,3-dione (5.2g) prepared in Step 1 above, methanol (30ml) and sulfuric acid
20 (1.6ml) were added. The reaction mixture was refluxed for 18 hours, cooled to room temperature, and concentrated in vacuo. To the resulting residue, 1N hydrochloric acid and dichloromethane were added. The water layer was adjusted to pH 12 with potassium hydroxide solution and extracted with dichloromethane. The extract was washed with water, dried
25 over sodium sulfate, and concentrated in vacuo to give 2.4g of the titled compound.

Step 3 : 1-methyl-7-fluoro-1,2,3,4-tetrahydroisoquinoline

30 To the solution of 1-methyl-7-fluoro-3,4-dihydroisoquinoline (2.4g, 14.7mmol) prepared in Step 2 in methanol (10ml), sodium borohydride (0.28g, 1 eq.) was portionwise added. The reaction mixture was stirred for 3 hours and 1N hydrochloric acid solution (20ml) was added thereto. The

reaction mixture was washed with dichloromethane. The water layer was adjusted to pH 12 with potassium hydroxide solution and extracted with dichloromethane. The extract was washed with water, dried over anhydrous sodium sulfate, and concentrated in vacuo to give 2.0g of the
5 titled compound.

Preparation 3 : Preparation of 1-methyl-6-fluoro-1,2,3,4-tetrahydroiso-quinoline

10 The same procedures as in Preparation 2 above were repeated using N-[2-(3-fluorophenyl)ethyl]acetamide (13.7g, 75.5mmol) prepared in accordance with the same procedure as in Step 1 of Preparation 1 as a starting material to afford 6.95g of the titled compound.

15 Preparation 4 : Preparation of 1-methyl-5-fluoro-1,2,3,4-tetrahydroiso-quinoline

The same procedures as in Preparation 2 above were repeated using N-[2-(2-fluorophenyl)ethyl]acetamide (4.36g, 24.06mmol) prepared
20 in accordance with the same procedure as in Step 1 of Preparation 1 as a starting material to afford 1.2g of the titled compound.

Preparation 5 : Preparation of 1-methyl-7-chloro-1,2,3,4-tetrahydroiso-quinoline

25 The same procedures as in Preparation 2 above were repeated using N-[2-(4-chlorophenyl)ethyl]acetamide (3.8g, 19.2mmol) prepared in accordance with the same procedure as in Step 1 of Preparation 1 as a starting material to afford 1.5g of the titled compound.

30 Preparation 6 : Preparation of 1-methyl-6-chloro-1,2,3,4-tetrahydroiso-quinoline

The same procedures as in Preparation 2 above were repeated using N-[2-(3-chlorophenyl)ethyl]acetamide (12.55g, 63.5mmol) prepared in accordance with the same procedure as in Step 1 of Preparation 1 as a starting material to afford 4.56g of the titled compound.

5

Preparation 7 : Preparation of 1-methyl-5-chloro-1,2,3,4-tetrahydroisoquinoline

The same procedures as in Preparation 2 above were repeated using N-[2-(2-chlorophenyl)ethyl]acetamide (12.55g, 63.5mmol) prepared in accordance with the same procedure as in Step 1 of Preparation 1 as a starting material to afford 5.8g of the titled compound.

Example 1 : Preparation of 5,6-dimethyl-2-(3,4-difluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

To the solution of 5,6-dimethyl-2-chloro-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine (0.5g, 1.74mmol) prepared in accordance with WO 96/05177 in propylene glycol (2ml), were added triethylamine (0.3ml, 2.09mmol) and 3,4-difluoroaniline (0.2ml, 2.09mmol). The reaction mixture was heated to 140°C, stirred for 18 hours, and cooled to room temperature. The resulting solution was diluted with dichloromethane, washed with water, and dried over anhydrous sodium sulfate. The organic layer was concentrated in vacuo. The resulting residue was subjected to silica gel column chromatography (eluent : ethyl acetate/hexane = 1/3), and then treated with ethyl ether solution saturated with hydrochloric acid to afford 0.1g (13.8%) of the titled compound.

NMR(CDCl₃) : δ 1.6 (d, 3H), 2.2 (s, 3H), 2.4 (s, 3H), 2.9 (m, 1H), 3.2 (m, 1H), 3.6 (m, 1H), 4.2 (m, 1H), 5.4 (q, 1H), 7.1 (m, 6H), 7.8 (m, 1H), 10.5 (s, 1H), 14.0 (s, 1H).

Example 2 : Preparation of 5,6-dimethyl-2-(2,4-difluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

To the solution of 5,6-dimethyl-2-chloro-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine (0.8g, 2.78mmol) in dimethyl sulfoxide (1.5ml), was added 2,4-difluoroaniline (0.5ml, 4.9mmol). The reaction mixture was heated to 120°C, stirred for 2 hours, and cooled to room temperature. The resulting solution was diluted with ethyl acetate, washed with water and sodium hydroxide solution, and dried over anhydrous magnesium sulfate. The organic layer was concentrated in vacuo. The resulting residue was subjected to silica gel column chromatography (eluent : ethyl acetate/dichloromethane = 1/5), and then treated with ethyl ether solution saturated with hydrochloric acid to afford 0.2g (17 %) of the titled compound.

NMR(CDCl₃): δ 1.6 (d, 3H), 2.2 (s, 3H), 2.6 (s, 3H), 2.8 (m, 1H), 3.1 (m, 1H), 3.5 (m, 1H), 4.2 (m, 1H), 5.3 (q, 1H), 6.9-7.2 (m, 6H), 7.8 (q, 1H), 9.7 (s, 1H), 14.4 (bs, 1H).

Example 3 : Preparation of 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-7-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

Step 1 : 5,6-dimethyl-2-chloro-4-(1-methyl-7-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine

To the solution of the compound (1.6g, 9.7mmol) prepared in Preparation 2 in dimethylformamide (5ml), were added 5,6-dimethyl-2,4-dichloropyrimidine (1.71g, 9.7mmol) prepared in accordance with WO 96/05177 and triethylamine (1.62ml). The reaction mixture was stirred for 5 hours at 70°C, cooled to room temperature, and diluted with dichloromethane. The resulting mixture was washed with water, dried over anhydrous sodium sulfate, and concentrated in vacuo. The resulting

residue was subjected to silica gel column chromatography (eluent : ethyl acetate/hexane = 1/5) to give 1.2g (40.2 %) of the titled compound .

Step 2 : 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-7-fluoro-
5 1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

To the solution of the compound (0.1g, 0.33mmol) prepared in Step 1 above in dimethylformamide (5ml), was added 4-fluoroaniline (0.08ml, 0.84mmol). The reaction mixture was refluxed for 3 hours,
10 cooled to room temperature, diluted with dichloromethane, and washed with water. The extracted dichloromethane layer was adjusted to basic with sodium hydroxide solution, washed with water, dehydrated, and concentrated. The resulting residue was subjected to silica gel column chromatography (eluent : ethyl acetate/n-hexane = 1/3), and then treated
15 with ethyl ether solution saturated with hydrochloric acid to afford 75 mg (54.5 %) of the titled compound.

NMR(CDCl₃): δ 1.5 (d, 3H), 2.1 (s, 3H), 2.3 (s, 3H), 2.7 (d, 1H), 3.1 (m, 1H), 3.5 (m, 1H), 4.2 (m, 1H), 5.3 (q, 1H), 6.7-7.2 (m, 5H), 7.4 (m, 2H),
20 10.2 (s, 1H), 14.0 (bs, 1H).

Example 4 - 13

The same procedures as in Step 2 of Example 3 above were
25 repeated using 5,6-dimethyl-2-chloro-4-(1-methyl-7-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine (0.1g, 0.33mmol) and the corresponding aniline derivatives (0.84mmol) to afford the following titled compounds.

30 Example 4 : Preparation of 5,6-dimethyl-2-phenylamino-4-(1-methyl-7-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

NMR(CDCl₃): δ 1.6 (d, 3H), 2.2 (s, 3H), 2.5 (s, 3H), 2.9 (m, 1H) 3.1 (m,

1H), 3.6 (m, 1H), 4.3 (m, 1H), 5.4 (q, 1H), 6.7-7.0 (m, 2H), 7.0-7.5 (m, 4H), 7.6(d, 2H), 10.2 (s, 1H), 14.1 (bs, 1H).

5 Example 5 : Preparation of 5,6-dimethyl-2-(2-methylphenylamino)-4-(1-methyl-7-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

NMR(CDCl₃): δ 1.6 (d, 3H), 2.3 (s, 3H), 2.4 (s, 3H), 2.5 (d, 3H), 2.8 (m, 1H) 3.1 (m, 1H), 3.6 (m, 1H), 4.2 (m, 1H), 5.3 (q, 1H), 6.7-7.0 (m, 2H),
10 7.0-7.4 (m, 3H), 7.6 (m, 1H), 9.5 (s, 1H), 14.4 (bs, 1H).

Example 6 : Preparation of 5,6-dimethyl-2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-7-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

15 NMR(CDCl₃): δ 1.5 (d, 3H), 2.2 (s, 3H), 2.4 (s, 3H), 2.5 (s, 3H), 2.8 (m, 1H) 3.0 (m, 1H), 3.5 (m, 1H), 4.2 (m, 1H), 5.2 (q, 1H), 6.7 (d, 1H), 6.8-7.0 (m, 3H), 7.1 (m, 1H), 7.5 (m, 1H), 9.5 (s, 1H), 14.3 (bs, 1H).

20 Example 7 : Preparation of 5,6-dimethyl-2-(3,4-difluorophenylamino)-4-(1-methyl-7-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

NMR(CDCl₃): δ 1.7 (d, 3H), 2.2 (s, 3H), 2.5 (s, 3H), 2.9 (m, 1H) 3.2 (m,
25 1H), 3.6 (m, 1H), 4.3 (m, 1H), 5.4 (q, 1H), 6.7-7.0 (m, 2H), 7.1 (m, 3H), 7.7 (m, 1H), 10.5 (s, 1H), 14.1 (bs, 1H).

Example 8 : Preparation of 5,6-dimethyl-2-(2,4-difluorophenylamino)-4-(1-methyl-7-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

30 NMR(CDCl₃): δ 1.5 (d, 3H), 2.2 (s, 3H), 2.5 (s, 3H), 2.8 (m, 1H) 3.1 (m, 1H), 3.5 (m, 1H), 4.2 (m, 1H), 5.2 (q, 1H), 6.7 (m, 2H), 6.9 (m, 2H), 7.1

(m, 1H), 7.6 (m, 1H), 10.2 (s, 1H), 14.1 (bs, 1H).

Example 9 : Preparation of 5,6-dimethyl-2-(4-chlorophenylamino)-4-(1-methyl-7-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine

5 hydrochloride

NMR(CDCl₃): δ 1.7 (d, 3H), 2.2 (s, 3H), 2.5 (s, 3H), 2.9 (m, 1H) 3.1 (m, 1H), 3.6 (m, 1H), 4.3 (m, 1H), 5.4 (q, 1H), 6.7-7.0 (m, 2H), 7.1 (m, 1H), 7.3 (t, 2H), 7.5 (d, 2H), 10.4(s, 1H), 14.1(bs, 1H).

10

Example 10 : Preparation of 5,6-dimethyl-2-(3,4-dichlorophenylamino)-4-(1-methyl-7-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine
hydrochloride

15 NMR(CDCl₃): δ 1.7 (d, 3H), 2.2 (s, 3H), 2.5 (s, 3H), 2.9 (m, 1H) 3.2 (m, 1H), 3.6 (m, 1H), 4.3 (m, 1H), 5.5 (q, 1H), 6.7-7.0 (m, 2H), 7.2 (m, 1H), 7.3 (m, 1H), 7.4 (d, 1H), 8.2 (s, 1H), 10.6(s, 1H), 14.1(bs, 1H).

Example 11 : Preparation of 5,6-dimethyl-2-(2-fluorophenylamino)-4-(1-methyl-7-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine
20 hydrochloride

NMR(CDCl₃): δ 1.5 (d, 3H), 2.2 (s, 3H), 2.5 (s, 3H), 2.8 (m, 1H) 3.1 (m, 1H), 3.5 (m, 1H), 4.2 (m, 1H), 5.3 (q, 1H), 6.7 (d, 1H), 6.9 (m, 1H), 7.0-
25 7.4 (m, 4H), 7.7 (t, 1H), 9.8 (s, 1H), 14.6 (bs, 1H).

Example 12 : Preparation of 5,6-dimethyl-2-(3-fluorophenylamino)-4-(1-methyl-7-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine
hydrochloride

30

NMR(CDCl₃): δ 1.7 (d, 3H), 2.2 (s, 3H), 2.5 (s, 3H), 2.9 (m, 1H) 3.2 (m, 1H), 3.6 (m, 1H), 4.3 (m, 1H), 5.4 (q, 1H), 7.9 (m, 3H), 7.1-7.4 (m, 3H), 7.6 (d, 1H), 10.5(s, 1H), 14.2(bs, 1H).

Example 13 : Preparation of 5,6-dimethyl-2-(3-chlorophenylamino)-4-(1-methyl-7-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

5

NMR(CDCl₃): δ 1.7 (d, 3H), 2.2 (s, 3H), 2.5 (s, 3H), 2.9 (m, 1H) 3.2 (m, 1H), 3.6 (m, 1H), 4.3 (m, 1H), 5.5 (q, 1H), 6.8-7.4 (m, 6H), 8.0(s, 1H), 10.5(s, 1H), 14.1(bs, 1H).

10 Example 14 : Preparation of 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-6-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

Step 1 : 5,6-dimethyl-2-chloro-4-(1-methyl-6-fluoro-1,2,3,4-tetrahydro-
15 isoquinolin-2-yl)pyrimidine

The same procedures as in Step 1 of Example 3 above were repeated using the compound (3.2g, 19.4mmol) prepared in Preparation 3, 5,6-dimethyl-2,4-dichloropyrimidine (3.42g, 19.4mmol), and
20 triethylamine (3.24ml) to afford 2.6g (43.8%) of the titled compound.

Step 2 : 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-6-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

25 The same procedures as in Step 2 of Example 3 above were repeated using 5,6-dimethyl-2-chloro-4-(1-methyl-6-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine (0.1g, 0.33mmol), dimethylformamide (5ml), and 4-fluoroaniline (0.08ml, 0.84mmol) to afford 84 mg (61 %) of the titled compound.

30

NMR(CDCl₃): δ 1.5 (d, 3H), 2.1 (s, 3H), 2.4 (s, 3H), 3.1 (m, 1H), 3.5 (m, 1H), 4.2 (m, 1H), 5.3 (q, 1H), 6.7-7.2 (m, 5H), 7.5 (m, 2H), 10.2 (s, 1H), 14.1 (bs, 1H).

Example 15 - 23

The same procedures as in Step 2 of Example 3 above were
5 repeated using 5,6-dimethyl-2-chloro-4-(1-methyl-6-fluoro-1,2,3,4-
tetrahydroisoquinolin-2-yl)pyrimidine (0.1g, 0.33mmol) prepared in Step
1 of Example 14 and the corresponding aniline derivatives (0.84mmol) to
afford the following titled compounds.

10 Example 15 : Preparation of 5,6-dimethyl-2-phenylamino-4-(1-methyl-6-
fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

NMR(CDCl₃): δ 1.6 (d, 3H), 2.2 (s, 3H), 2.5 (s, 3H), 2.8 (m, 1H), 3.2
(m, 1H), 3.6 (m, 1H), 4.3 (m, 1H), 5.4 (q, 1H), 6.8-7.6 (m, 8H), 10.2 (s,
15 1H).

Example 16 : Preparation of 5,6-dimethyl-2-(2-methylphenylamino)-4-(1-
methyl-6-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine
hydrochloride

20 NMR(CDCl₃): δ 1.6 (d, 3H), 2.2 (s, 3H), 2.4 (m, 3H), 2.5 (s, 3H) 2.8 (m,
1H), 3.1 (m, 1H), 3.5 (m, 1H), 4.2 (m, 1H), 5.3 (q, 1H), 6.8 - 7.1 (m, 3H),
7.2 (m, 3H), 7.6 (d, 1H), 9.5 (s, 1H), 14.4(bs, 1H).

25 Example 17 : Preparation of 5,6-dimethyl-2-(2-methyl-4-
fluorophenylamino)-4-(1-methyl-6-fluoro-1,2,3,4-tetrahydroisoquinolin-
2-yl)pyrimidine hydrochloride

NMR(CDCl₃): δ 1.5 (d, 3H), 2.2 (s, 3H), 2.4 (s, 3H), 2.5 (s, 3H), 2.8 (m,
30 1H) 3.1 (m, 1H), 3.5 (m, 1H), 4.2 (m, 1H), 5.2 (q, 1H), 6.8-7.1 (m, 5H),
7.5 (m, 1H), 9.6 (s, 1H), 14.4 (bs, 1H).

Example 18 : Preparation of 5,6-dimethyl-2-(3,4-difluorophenylamino)-4-

(1-methyl-6-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine
hydrochloride

NMR(CDCl₃): δ 1.7 (d, 3H), 2.2 (s, 3H), 2.5 (s, 3H), 2.9 (m, 1H) 3.2 (m,
5 1H), 3.6 (m, 1H), 4.3 (m, 1H), 5.4 (q, 1H), 6.8-7.3 (m, 5H), 7.8 (m, 1H),
10.5(s, 1H).

Example 19 : Preparation of 5,6-dimethyl-2-(2,4-difluorophenylamino)-4-
(1-methyl-6-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine
10 hydrochloride

NMR(CDCl₃): δ 1.5 (d, 3H), 2.2 (s, 3H), 2.5 (s, 3H), 2.8 (m, 1H) 3.1 (m,
1H), 3.5 (m, 1H), 4.2 (m, 1H), 5.2 (q, 1H), 6.7-7.0 (m, 5H), 7.6 (m, 1H),
9.5(s, 1H).

15 Example 20 : Preparation of 5,6-dimethyl-2-(4-chlorophenylamino)-4-(1-
methyl-6-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine
hydrochloride

20 NMR(CDCl₃): δ 1.7 (d, 3H), 2.2 (s, 3H), 2.5 (s, 3H), 2.9 (m, 1H), 3.2
(m, 1H), 3.6 (m, 1H), 4.3 (m, 1H), 5.4 (q, 1H), 6.8-7.2 (m, 4H), 7.3 (t, 2H),
7.5 (d, 1H), 10.4 (s, 1H), 14.1(bs, 1H).

Example 21 : Preparation of 5,6-dimethyl-2-(2-fluorophenylamino)-4-(1-
25 methyl-6-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine
hydrochloride

NMR(CDCl₃): δ 1.5 (d, 3H), 2.2 (s, 3H), 2.5 (s, 3H), 2.8 (m, 1H), 3.2
(m, 1H), 3.6 (m, 1H), 4.2 (m, 1H), 5.3 (q, 1H), 6.7-7.1 (m, 4H), 7.2 (m,
30 2H), 7.8 (m, 1H), 9.4 (s, 1H).

Example 22 : Preparation of 5,6-dimethyl-2-(3-fluorophenylamino)-4-(1-
methyl-6-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine

hydrochloride

NMR(CDCl₃): δ 1.7 (d, 3H), 2.3 (s, 3H), 2.5 (s, 3H), 2.9 (m, 1H), 3.2 (m, 1H), 3.6 (m, 1H), 4.3 (m, 1H), 5.5 (q, 1H), 6.8-7.0 (m, 3H), 7.1-7.4 (m, 3H), 7.7 (d, 1H), 10.5 (s, 1H), 14.1 (bs, 1H).

Example 23 : Preparation of 5,6-dimethyl-2-(3-chlorophenylamino)-4-(1-methyl-6-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

10

NMR(CDCl₃): δ 1.7 (d, 3H), 2.3 (s, 3H), 2.5 (s, 3H), 3.0 (m, 1H), 3.3 (m, 1H), 3.7 (m, 1H), 4.3 (m, 1H), 5.5 (q, 1H), 6.8-7.1 (m, 3H), 7.1-7.4 (m, 3H), 8.1 (s, 1H), 10.5 (s, 1H), 14.1 (bs, 1H).

15 Example 24 : Preparation of 5-methyl-6-fluoromethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-pyrimidine hydrochloride

The solution of 6-hydroxymethyl-5-methyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine (0.19g, 0.5mmol) prepared in accordance with WO 98/43968 in dichloromethane (5ml) and cooled to -75°C and (diethylamino)sulfur trifluoride (0.15ml, 2.26mmol) was dropwise added thereto. The reaction mixture was stirred for 2 hours at -75°C, further stirred for 2 hours at -45°C, and slowly heated to room temperature. The reaction mixture was stirred for 18 hours at room temperature, and then water was added thereto to terminate the reaction. The extracted organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue was subjected to silica gel column chromatography (eluent : ethyl acetate/hexane=1/3), and then treated with ethyl ether solution saturated with hydrochloric acid to afford 72mg (34.5%) of the titled compound.

NMR (DMSO-d₆): δ 1.6(d, 3H), 2.2(s, 3H), 2.8(m, 1H), 3.1(m, 1H), 3.5(m, 1H), 4.2(m, 1H), 5.3(q, 1H), 5.5(d, 2H), 7.2(m, 6H), 7.6(m, 2H), 10.0(br, 1H).

5 Example 25 : Preparation of 5-fluoromethyl-6-methyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-pyrimidine hydrochloride

The same procedures as in Example 24 above were repeated using
10 5-hydroxymethyl-6-methyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine (0.19g, 0.5mmol) prepared in accordance with WO 98/43968, dichloromethane (5ml), and (diethylamino)sulfur trifluoride (0.15ml, 2.26mmol) to afford 27 mg (14%) of the titled compound.

15

NMR(CDCl₃): δ 1.6(d, 3H), 2.2(s, 3H), 2.7(m, 1H), 3.1(m, 1H), 3.5(m, 1H), 4.0(m, 1H), 5.1(m, 2H), 5.4(s, 1H), 6.9(m, 3H), 7.1(m, 4H), 7.5(m, 2H).

20 Example 26 : Preparation of 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-fluoromethyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

The same procedures as in Example 24 above were repeated using
25 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-hydroxymethyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine(0.1g, 0.26mmol) prepared in accordance with WO 98/43968, dichloromethane (5ml), and (diethylamino)sulfur trifluoride (77 μ l, 0.58mmol) to afford 0.1g (92.2 %) of the titled compound.

30 NMR (DMSO-d₆) : δ 2.2 (d, 6H), 3.0 (m, 1H), 3.9 (m, 1H), 4.4 (m, 2H), 5.0 (m, 1H), 5.6 (m, 1H), 7.2 (m, 6H), 7.6 (m, 2H).

Example 27 : Preparation of 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-

methyl-5-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine
hydrochloride

Step 1 : 5,6-dimethyl-2-chloro-4-(1-methyl-5-fluoro-1,2,3,4-tetrahydro-
5 isoquinolin-2-yl)pyrimidine

The same procedures as in Step 1 of Example 3 above were repeated using the compound (1.2g, 7.3mmol) prepared in Preparation 4, dimethylformamide (10ml), 5,6-dimethyl-2,4-dichloropyrimidine (1.3g,
10 7.3mmol), and triethylamine (1.22ml) to afford 0.94g (42%) of the titled compound.

Step 2 : 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-5-fluoro-
1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

15

The same procedures as in Step 2 of Example 3 above were repeated using 5,6-dimethyl-2-chloro-4-(1-methyl-5-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine (0.1g, 0.33mmol) prepared in Step 1 above, dimethylformamide (5ml), and 4-fluoroaniline (0.08ml,
20 0.84mmol) to afford 75 mg (54.5 %) of the titled compound.

25

Example 28 : Preparation of 5,6-dimethyl-2-phenylamino-4-(1-methyl-5-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

The same procedures as in Step 2 of Example 3 above were
30 repeated using 5,6-dimethyl-2-chloro-4-(1-methyl-5-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine (0.1g, 0.33mmol) prepared in Step 1 of Example 27 and aniline (0.84mmol) to afford 82 mg (59.6 %) of the titled compound.

NMR(CDCl₃): δ 1.6 (d, 3H), 2.2 (s, 3H), 2.5 (s, 3H), 3.2 (m, 1H), 3.5 (m, 1H), 4.3 (m, 1H), 5.4 (q, 1H), 6. 8-7.2 (m, 6H), 7.51 (m, 2H), 10.2 (s, 1H), 14.1 (bs, 1H).

5

Example 29 : Preparation of 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-7-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

10 Step 1 : 5,6-dimethyl-2-chloro-4-(1-methyl-7-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine

The same procedures as in Step 1 of Example 3 above were repeated using the compound (1.5g, 8.26mmol) prepared in Preparation 5,
15 dimethylformamide (10ml), 5,6-dimethyl-2,4-dichloropyrimidine (1.46g, 8.26mmol), and triethylamine(1.38ml) to afford 1.12g (41%) of the titled compound.

Step 2 : 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-7-chloro-
20 1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

The same procedures as in Step 2 of Example 3 above were repeated using 5,6-dimethyl-2-chloro-4-(1-methyl-7-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine (0.1g, 0.31mmol) prepared in Step
25 1 above, dimethylformamide (5ml), and 4-fluoroaniline (0.07ml, 0.74mmol) to afford 82 mg (61.3 %) of the titled compound

NMR(CDCl₃): δ 1.6 (d, 3H), 2.2 (s, 3H), 2.4 (s, 3H), 2.8 (d, 1H), 3.1 (m, 1H), 3.6 (m, 1H), 4.2 (m, 1H), 5.3 (q, 1H), 6.9-7.2 (m, 5H), 7.5 (m, 2H),
30 10.2 (s, 1H), 14.1 (bs, 1H).

Example 30 - 32

The same procedures as in Step 2 of Example 3 above were repeated using 5,6-dimethyl-2-chloro-4-(1-methyl-7-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine (0.1g, 0.31mmol) prepared in Step 1 of Example 29 and the corresponding aniline derivatives (0.74mmol) to afford following titled compounds.

Example 30 : Preparation of 5,6-dimethyl-2-phenylamino-4-(1-methyl-7-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

NMR(CDCl₃): δ 1.6 (d, 3H), 2.2 (s, 3H), 2.5 (s, 3H), 2.9 (d, 1H), 3.2 (m, 1H), 3.6 (m, 1H), 4.3 (m, 1H), 5.4 (q, 1H), 7.0-7.5 (m, 6H), 7.6 (m, 2H), 10.2 (s, 1H), 14.1 (bs, 1H).

Example 31 : Preparation of 5,6-dimethyl-2-(2-methylphenylamino)-4-(1-methyl-7-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

NMR(CDCl₃): δ 1.5 (d, 3H), 2.2 (s, 3H), 2.4 (s, 3H), 2.5 (s, 3H), 2.8 (d, 1H), 3.0 (m, 1H), 3.5 (m, 1H), 4.2 (m, 1H), 5.2 (q, 1H), 6.9-7.3 (m, 6H), 7.6 (d, 1H), 9.5 (s, 1H), 14.5 (bs, 1H).

Example 32 : Preparation of 5,6-dimethyl-2-(3,4-difluorophenylamino)-4-(1-methyl-7-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

NMR(CDCl₃): δ 1.7 (d, 3H), 2.2 (s, 3H), 2.5 (s, 3H), 2.9 (d, 1H), 3.2 (m, 1H), 3.6 (m, 1H), 4.3 (m, 1H), 5.4 (q, 1H), 7.0-7.4 (m, 5H), 7.7 (m, 1H), 10.5 (s, 1H), 14.1 (bs, 1H).

Example 33 : Preparation of 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

Step 1 : 5,6-dimethyl-2-chloro-4-(1-methyl-6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine

The same procedures as in Step 1 of Example 3 above were repeated using the compound (4.5g, 24.77mmol) prepared in Preparation 6, dimethylformamide (15ml), 5,6-dimethyl-2,4-dichloropyrimidine (4.39g, 24.77mmol), and triethylamine (4.14ml) to afford 3.43g (43%) of the titled compound.

Step 2 : 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

The same procedures as in Step 2 of Example 3 above were repeated using 5,6-dimethyl-2-chloro-4-(1-methyl-6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine (0.1g, 0.31mmol) prepared in Step 1 above, dimethylformamide (5ml), and 4-fluoroaniline (0.07ml, 0.74mmol) to afford 71mg (53 %) of the titled compound.

NMR(CDCl₃): δ 1.6 (d, 3H), 2.2 (s, 3H), 2.5 (s, 3H), 2.9 (m, 1H), 3.2 (m, 1H), 3.6 (m, 1H), 4.3 (m, 1H), 5.4 (q, 1H), 6.9-7.3 (m, 4H), 7.5 (m, 2H), 10.2 (s, 1H), 14.1 (bs, 1H).

Example 34 : Preparation of 5,6-dimethyl-2-phenylamino-4-(1-methyl-6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

25

The same procedures as in Step 2 of Example 3 above were repeated using 5,6-dimethyl-2-chloro-4-(1-methyl-6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine (0.1g, 0.31mmol) prepared in Step 1 of Example 33 and aniline (0.74mmol) to afford 73mg (54.3 %) of the titled compound

30

NMR(CDCl₃): δ 1.6 (d, 3H), 2.2 (s, 3H), 2.5 (s, 3H), 2.9 (m, 1H), 3.2 (m, 1H), 3.6 (m, 1H), 4.3 (m, 1H), 5.4 (q, 1H), 7.1 (d, 1H), 7.2 (m, 3H),

7.4 (m, 2H), 7.6 (d, 2H), 10.2 (s, 1H), 14.1 (bs, 1H).

Example 35 : Preparation of 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-5-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine

5 hydrochloride

Step 1 : 5,6-dimethyl-2-chloro-4-(1-methyl-5-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine

10 The same procedures as in Step 1 of Example 3 were repeated using the compound (4.5g, 24.77mmol) prepared in Preparation 7, dimethylformamide (15ml), 5,6-dimethyl-2,4-dichloropyrimidine (4.39g, 24.77mmol), and triethylamine (4.14ml) to afford 3.21g (40.2%) of the titled compound.

15

Step 2 : 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-5-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

The same procedures as in Step 2 of Example 3 above were
20 repeated using 5,6-dimethyl-2-chloro-4-(1-methyl-5-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine (0.1g, 0.31mmol) prepared in Step 1 above, dimethylformamide (5ml), and 4-fluoroaniline (0.07ml, 0.74mmol) to afford 67 mg (50 %) of the titled compound.

25 NMR(CDCl₃): δ 1.6 (d, 3H), 2.2 (s, 3H), 2.5 (s, 3H), 3.1 (m, 1H), 3.6 (m, 1H), 4.3 (m, 1H), 5.4 (q, 1H), 6.9-7.4 (m, 5H), 7.5(m, 2H), 10.2 (s, 1H).

Example 36 - 44

30

The same procedures as in Step 2 of Example 3 above were repeated using 5,6-dimethyl-2-chloro-4-(1-methyl-5-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine (0.1g, 0.31mmol) prepared in Step

1 of Example 35 and the corresponding aniline derivatives (0.74mmol) to afford the following the titled compound.

5 Example 36 : Preparation of 5,6-dimethyl-2-phenylamino-4-(1-methyl-5-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

NMR(CDCl₃): δ 1.6 (d, 3H), 2.2 (s, 3H), 2.4 (s, 3H), 3.1 (m, 1H), 3.5 (m, 1H), 4.3 (m, 1H), 5.3 (q, 1H), 6.8-7.2 (m, 6H), 7.5 (m, 2H), 10.2 (s, 1H), 14.1 (bs, 1H).

10

Example 37 : Preparation of 5,6-dimethyl-2-(2-methylphenylamino)-4-(1-methyl-5-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

15 NMR(CDCl₃): δ 1.6 (d, 3H), 2.2 (s, 3H), 2.4 (s, 3H), 2.5 (s, 3H), 3.0 (m, 2H), 3.5 (m, 1H), 4.3 (m, 1H), 5.3 (q, 1H), 6.9 (d, 1H), 7.0-7.4 (m, 5H), 7.6 (d, 1H), 9.6 (s, 1H).

20 Example 38 : Preparation of 5,6-dimethyl-2-(3,4-difluorophenylamino)-4-(1-methyl-5-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

25 NMR(CDCl₃): δ 1.7 (d, 3H), 2.2 (s, 3H), 2.5 (s, 3H), 3.1 (m, 2H), 3.6 (m, 1H), 4.4 (m, 1H), 5.5 (q, 1H), 7.0-7.4 (m, 5H), 7.7 (m, 1H), 10.5 (s, 1H), 14.1 (bs, 1H).

Example 39 : Preparation of 5,6-dimethyl-2-(2,4-difluorophenylamino)-4-(1-methyl-5-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

30

NMR(CDCl₃): δ 1.6 (d, 3H), 2.2 (s, 3H), 2.5 (s, 3H), 3.0 (m, 2H), 3.5 (m, 1H), 4.2 (m, 1H), 5.3 (q, 1H), 6.8-7.1 (m, 3H), 7.1-7.4 (m, 2H), 7.6 (m, 1H), 9.7 (s, 1H), 14.5 (bs, 1H).

Example 40 : Preparation of 5,6-dimethyl-2-(4-chlorophenylamino)-4-(1-methyl-5-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

5

NMR(CDCl₃): δ 1.7 (d, 3H), 2.2 (s, 3H), 2.5 (s, 3H), 3.1 (m, 2H), 3.6 (m, 1H), 4.3 (m, 1H), 5.4 (q, 1H), 7.1 (d, 1H), 7.1-7.4 (m, 5H), 7.6 (d, 1H), 10.4 (s, 1H), 14.1(bs, 1H).

10 Example 41 : Preparation of 5,6-dimethyl-2-(3,4-dichlorophenylamino)-4-(1-methyl-5-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

15 NMR(CDCl₃): δ 1.7 (d, 3H), 2.3 (s, 3H), 2.5 (s, 3H), 3.1 (m, 2H), 3.7 (m, 1H), 4.4 (m, 1H), 5.6 (q, 1H), 7.0 (d, 1H), 7.0-7.5 (m, 5H), 8.2 (s, 1H), 10.7 (s, 1H), 14.1 (bs, 1H).

20 Example 42 : Preparation of 5,6-dimethyl-2-(2-fluorophenylamino)-4-(1-methyl-5-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

NMR(CDCl₃): δ 1.6 (d, 3H), 2.3 (s, 3H), 2.6 (s, 3H), 3.0 (m, 2H), 3.6 (m, 1H), 4.3 (m, 1H), 5.4 (q, 1H), 7.0 (d, 1H), 7.1-7.4 (m, 5H), 7.7 (t, 1H), 9.8 (s, 1H), 14.6(bs, 1H).

25

Example 43 : Preparation of 5,6-dimethyl-2-(3-fluorophenylamino)-4-(1-methyl-5-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

30 NMR(CDCl₃): δ 1.7 (d, 3H), 2.3 (s, 3H), 2.5 (s, 3H), 3.1 (m, 2H), 3.6 (m, 1H), 4.4 (m, 1H), 5.5 (q, 1H), 6.9 (t, 1H), 7.1 (d, 1H), 7.2-7.4 (m, 4H), 7.7 (d, 1H), 10.5 (s, 1H), 14.1(bs, 1H).

Example 44 : Preparation of 5,6-dimethyl-2-(3-chlorophenylamino)-4-(1-methyl-5-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

5 NMR(CDCl₃): δ 1.7 (d, 3H), 2.3 (s, 3H), 2.5 (s, 3H), 3.1 (m, 2H), 3.7(m, 1H), 4.4 (m, 1H), 5.6 (q, 1H), 7.0-7.4 (m, 6H), 8.1 (s, 1H), 10.5(s, 1H), 14.1(bs, 1H).

Test Example 1 : Inhibition of proton pump (H⁺/K⁺-ATPase) activity

10

The gastric vesicle as an enzyme source was prepared by the same method as in the Experiment 1-1 of WO 94/14795. Further, the inhibitory effect of proton pump activity was measured by the same method as in Experiment 1-2 of WO 94/14795.

15

Namely, the proton pump activity stimulated by Mg⁺⁺ was used as a negative control group, and the activity stimulated by Mg⁺⁺ and K⁺ was used as a positive control group. Omeprazole was used as the control compound.

20

Test tubes were divided into 4 groups: Group 1 as negative control group (n=3), Group 2 as positive control group (n=3), Group 3 (n=5X2) to be administered with the compound of the present invention and Group 4 (n=5X2) to be administered with the control compound.

25

The inhibitory effects of Group 3 and 4 on proton pump activity were measured by employing the compounds prepared in Examples and omeprazole, respectively, each of which was dissolved in dimethyl sulfoxide (DMSO) at 5 different concentrations.

30

To each of Groups 1, 2, 3, and 4 was added 0.1ml of magnesium chloride (4mM) dissolved in 40mM Tris-HCl buffer (pH 6.4) and 100 μ g of enzyme source. The 50 μ l of potassium chloride (60mM) and 50 μ l of

ammonium chloride (6mM) dissolved in 40mM Tris-HCl buffer (pH 6.4) were added to all groups except for Group 1.

10 $10\mu\ell$ of dimethyl sulfoxide was added to each of Group 1 and 2; and to Group 3 was added $10\mu\ell$ of dimethyl sulfoxide solution prepared by dissolving compound of Example at 5 different concentrations ($n=5 \times 2$). To Group 4, was added $10\mu\ell$ of the solution prepared by dissolving omeprazole in dimethyl sulfoxide at 5 different concentrations (40, 20, 10, 5, $2.5\mu\text{M}$) ($n=5 \times 2$). 40mM Tris-HCl buffer (pH 6.4) was added thereto so as to make the total volume $400\mu\ell$.

15 Thereafter, the test tubes of each Group were placed at 37°C for 30 minutes for the preincubation. ATP solution (6.6 mM) was added until the total volume became $500\mu\ell$. After the reaction was carried out at 37°C for 30 minutes, 25% cold trichloroacetic acid was added to terminate the enzyme reaction. The released inorganic phosphorous was measured by an automatic analyzer (Express 550, Corning).

20 The difference between Group 1 and Group 2 represents the proton pump activity activated by K^+ only. The IC_{50} s of Group 3 and 4 were calculated using the Linear Regression method. The concentrations of the test compounds inhibiting 50% of the proton pump activity are represented as IC_{50} in Table 1.

Table 1. Inhibitory effects on proton pump
(H⁺/K⁺-ATPase) activity

Compound	IC ₅₀ (μM)
Example 1	1.6
Example 2	3.8
Example 4	1.0
Example 5	0.6
Example 6	0.3
Example 7	2.6
Example 8	0.7
Example 9	0.9
Example 11	1.9
Example 12	3.2
Example 14	0.7
Example 17	0.2
Example 19	1.0
Example 20	1.2
Example 24	0.9
Example 25	4.1
Example 26	3.7
Example 35	0.9
Example 39	0.9
Omeprazole	11.5

5

As shown in Table 1, the compounds of the present invention exhibit the highly potent acid pump inhibitory activity over omeprazole.

Test Example 2 : Inhibition of gastric secretion

10

In accordance with the method disclosed in Shay, H., et al.,

Gastroenterology 5, 43-61 (1945), the inhibitory activity against acid secretion was evaluated.

Sprague-Dawley rats having a body weight of 200 ± 10 g were
5 divided into 3 groups (n=5) and deprived of food for 24 hours before the experiment with free access to water. Under ether anesthesia, the abdomen was incised, and the pylorus was ligated.

As a comparative group, Group 1 was administered
10 intraduodenally in the volume of 0.5ml/200g of 0.5% methylcellulose solution. Group 2 and 3 were administered intraduodenally in the volume of 0.5ml/200g of the compound of Example and omeprazole, respectively, each of which was suspended in 0.5% methylcellulose solution at a concentration of 10mg/kg. After 5 hours from ligation, the rats were
15 sacrificed, and the gastric contents were collected.

The gastric juice collected was centrifuged at 1,000g to remove precipitates. The volume and pH of the gastric juice were measured. Relative volumes, relative acid concentrations, and relative acid outputs of
20 the test compounds were calculated from equations (I), (II), and (III) and the results are shown in Table 2.

Relative volume ----- (I)
= (the average volume of gastric juice of Group 1 – the average volume
25 of gastric juice of Group 2)
/ (the average volume of gastric juice of Group 1 – the average volume
of gastric juice of Group 3)

Relative acid concentration ----- (II)
30 = (the average acidity of Group 1 - the average acidity of Group 2)
/ (the average acidity of Group 1 - the average acidity of Group 3)

Relative acid output ----- (III)

= (the total volume of acid output of Group 1 - the total volume of acid output of Group 2)
 / (the total volume of acid output of Group 1 - the total volume of acid output of Group 3)

5

Table 2.

Compound	Relative volume	Relative conc.	Relative acid output
Example 1	0.6	0.7	0.8
Example 2	0.9	0.7	0.9
Example 3	0.7	1.2	0.9
Example 4	0.9	1.1	0.9
Example 6	0.7	0.8	0.8
Example 14	1.9	1.3	1.3
Example 15	0.7	1.6	1.0
Example 16	1.0	0.9	0.9
Example 24	0.6	1.1	1.0
Example 29	0.9	1.2	1.0
Example 37	0.9	0.8	0.9


10

As shown in Table 2, the compounds of the present invention exhibit the highly potent inhibitory activity against gastric acid secretion over omeprazole.

What is claimed is :

1. A pyrimidine derivative of formula (I) or a pharmaceutically acceptable non-toxic salt thereof :

5




wherein R_1 is hydrogen, methyl, or halogen and R_2 , R_3 , R_4 , R_5 and R_6 are, independently each other, hydrogen or halogen, provided that when all of R_3 , R_4 , R_5 and R_6 are hydrogen, R_1 and R_2 are, independently each other, halogen.

10


2. The pyrimidine derivative of formula (I) or the pharmaceutically acceptable non-toxic salts thereof according to claim 1, wherein R_1 , R_2 , R_3 , R_4 , R_5 and R_6 are independently fluoro or chloro.

15

3. A process for preparing a pyrimidine derivative of formula (I-1), which comprises halogenating the corresponding hydroxy group of a compound of formula (II) :






(I-1)



(II)

wherein R_1 is hydrogen, methyl, or halogen and R_2 , R_3 , R_5 and R_6 are, independently each other, hydrogen or halogen, provided that one or more of R_3 , R_5 and R_6 is/are halogen; and R_3' , R_5' and R_6' is independently
 5 hydrogen or hydroxy, provided that one or more of R_3' , R_5' and R_6' are hydroxy.

4. A process for preparing a pyrimidine derivative of formula (I-2), which comprises reacting a compound of formula (III) with a compound of
 10 formula (IV) :



wherein R_1 is hydrogen, methyl, or halogen and R_2 and R_4 are,
 15 independently each other, hydrogen or halogen, provided that when R_4 is hydrogen, R_1 and R_2 are, independently each other, halogen.

5. A pharmaceutical composition for treating gastrointestinal diseases, which comprises a therapeutically effective amount of the pyrimidine derivative or a pharmaceutically acceptable non-toxic salt thereof defined
 20 in claim 1 as an active ingredient, and a pharmaceutically acceptable carrier or excipient.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR 99/00669

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁷: C07D 401/04, A61K 31/506

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁷: C07D 401/04,

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

AT, Chemical Abstracts

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS, DARC: QUESTEL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97/42186 (YUHAN CORP.), 11 November 1997 (11.11.97), claims.	1-5
A	WO 98/18784 (YUHAN CORP.), 7 May 1998 (07.05.98), claims.	1-5
A	WO 96/05177 (YUHAN CORP.), 22 February 1996 (22.02.96), cited in the application; claims.	1-5
A	Han, Kye S.; Kim, Yoon G.; Yoo, Joong K.; Lee, Jong W.; Lee, Myung G. „Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats“, Biopharm. Drug Dispos. (1998), 19(8), 493-500 (abstract). Database [online]: Chemical Abstracts, Copyright 2000 American Chemical Society [retrieved on 11.01.00]. Retrieved from STN International, Karlsruhe. Chem. Abstr. No. 130:104764.	1, 5

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

„A“ document defining the general state of the art which is not considered to be of particular relevance

„E“ earlier application or patent but published on or after the international filing date

„L“ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

„O“ document referring to an oral disclosure, use, exhibition or other means

„P“ document published prior to the international filing date but later than the priority date claimed

„T“ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

„X“ document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

„Y“ document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

„&“ document member of the same patent family

Date of the actual completion of the international search

12 January 1999 (12.01.00)

Date of mailing of the international search report

27 March 2000 (27.03.00)

Name and mailing address of the ISA/AT
Austrian Patent Office
Kohlmarkt 8-10; A-1014 Vienna
Facsimile No. 1/53424/535

Authorized officer

Müller

Telephone No. 1/53424/434

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 99/00669

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Ahn, Byung-Nak; Fujio, Naoki; Kusumoto, naotoshi; Abe, Yoshifumi; Odomi, Masaaki; Lee, Jong Wook „Pharmacokinetic study of YH1885 (I): absorption, distribution and excretion of ¹⁴ C-YH1885 in rats“, Yuhan Res. Cent., Yuhan Corp., Tangjeong-Dong, 435-030, S. Korea (abstract). [online] [retrieved on 11.01.00]. Retrieved from STN International, Karlsruhe. Chem. Abstr. No. 127:185317.	1,5
A	Han, Kye S.; Kim, Yoon G.; Lee, Jong W.; Lee, Myung G. „Blood partition and protein binding of a new reversible proton pump inhibitor, YH1885“ Biopharm. Drug Dispos. (1998), 19(6), 413-415 (abstract). [online] [retrieved on 11.01.00]. Retrieved from STN International, Karlsruhe. Chem. Abstr. No. 129:297919.	1,5
A	Kim, Hyeyoung; Kim, Dong goo; Lee, Bong Yong; Lee, Jong Wook; Kim, Kyung Hwan „Inhibitory effects of reversible proton pump inhibitors YH1238 and YH1885 on acid secretion in isolated gastric cells“, Korean J. Physiol. Pharmacol. (1997), 1(3), 337-343 (abstract). [online] [retrieved on 11.01.00]. Retrieved from STN International, Karlsruhe. Chem. Abstr. No. 127:257390.	1,5
A	Han, Kye Soo; Choi, Hyun-Cheol; Yoo, Joong-Keun; Lee, Jong Wook; Lee, Myung Gull „Determination of a new proton pump inhibitor, YH1885, in human plasma and urine by high-performance liquid chromatography“ J. Chromatogr., B: Biomed. Sci. Appl. (1997), 696(2), 312-316 (abstract). [online] [retrieved on 11.01.00]. Retrieved from STN International, Karlsruhe. Chem. Abstr. No. 127:214517.	1,5

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR 99/00669

Patent document cited in search report			Publication date	Patent family member(s)			Publication date
WO	A1	9742186	13-11-1997	AU	B2	712970	18-11-1999
				CN	A	1217722	26-05-1999
				EP	A1	900214	10-03-1999
				JP	T2	11509237	17-08-1999
				KR	B1	177294	20-03-1999
				US	A	5990311	23-11-1999
				KR	B1	177293	20-03-1999
				KR	B1	185292	01-05-1999
				WO	A1	9818784	07-05-1998
				AU	A1	27133/97	26-11-1997
WO	A1	9818784	07-05-1998	AU	B2	712970	18-11-1999
				CN	A	1217722	26-05-1999
				EP	A1	900214	10-03-1999
				JP	T2	11509237	17-08-1999
				KR	B1	185292	01-05-1999
				US	A	5990311	23-11-1999
				WO	A1	9742186	13-11-1997
				AU	A1	27133/97	26-11-1997
				KR	B1	177293	20-03-1999
				KR	B1	177294	20-03-1999
WO	A1	9605177	22-02-1996	AU	A1	31225/95	07-03-1996
WO	A1	9605177	22-02-1996	AU	B2	688087	05-03-1998
				CA	AA	2197298	22-02-1996
				JP	B2	2896532	31-05-1999
				KR	B1	157075	16-11-1998
				US	A	5750531	12-05-1998
				EP	A1	775120	28-05-1997
				JP	T2	9509188	16-09-1997